SALAMOL

This brand name is authorized in Cyprus, Hong Kong SAR China, Ireland, Malta, Netherlands, New Zealand, UK.

Active ingredients

The drug SALAMOL contains one active pharmaceutical ingredient (API):

1	Salbutamol UNII 021SEF3731 - ALBUTEROL SULFATE
	Salbutamol is a selective β2-agonist providing short-acting (4-6 hour) bronchodilation with a fast onset (within 5 minutes) in reversible airways obstruction. At therapeutic doses it acts on the β2-adrenoceptors of bronchial muscle. Salbutamol is administered for the symptomatic relief of bronchospasm associated with chronic or acute asthma, bronchitis or other obstructive pulmonary diseases.
	Read more about Salbutamol

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SALAMOL Pressurised inhalation, suspension	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
R03AC02	Salbutamol	R Respiratory system → R03 Drugs for obstructive airway diseases → R03A Adrenergics, inhalants → R03AC Selective beta-2-adrenoreceptor agonists
Discover more medicines within R03AC02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
GB	Medicines & Healthcare Products Regulatory Agency	14814, 32156, 373954
HK	Department of Health Drug Office	50198
IE	Health Products Regulatory Authority	44811, 44845, 44868, 44897, 44898
MT	Medicines Authority	AA565/54001
NL	Z-Index G-Standaard, PRK	27847, 31941
NZ	Medicines and Medical Devices Safety Authority	11428